The rise of Sildenafil initially sparked a surge for major pharmaceutical companies, but recent changes present a murky scenario for those considering a stake. Generic alternatives are eating into earnings, and ongoing https://zoewjpv473043.targetblogs.com/41490798/the-blue-pill-and-big-pharma-a-risky-bet